

EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 51ST ASCO ANNUAL MEETING
HIGHLIGHTS INCLUDE NEW CLINICAL DATA ON HALAVEN® (ERIBULIN) IN SOFT TISSUE SARCOMA AND ON LENVIMA® (LENVATINIB) IN RENAL CELL CARCINOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting new study results on Halaven® (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, “eribulin”) and Lenvima® (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, “lenvatinib”) will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.

The main presentations for this year’s ASCO meeting include an oral presentation highlighting the results of a Phase III clinical study (Study 309) of eribulin in soft tissue sarcoma to be given on Monday, June 1. Furthermore, these findings have been chosen by ASCO to be featured in a press conference as part of the official press program starting at 10:30 a.m. (CDT) on Saturday, May 30.

For lenvatinib, an oral presentation on the results of a Phase II clinical study (Study 205) of the agent in metastatic renal cell carcinoma will also be given on Monday, June 1.

In addition, the poster sessions include a presentation of the results of an analysis concerning biomarkers of response and resistance in the Phase III study of lenvatinib in ¹³¹I-refractory differentiated thyroid cancer (SELECT study).

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

Oral Presentations:

Product	
<p>Abstract No: LB100 Lenvatinib (Lenvima®)</p>	<p align="center">Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI)</p> <p align="center">Oral Presentation June 1 (Mon), 15:48-16:00</p> <p align="center">Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)</p>
<p>Abstract No: 4506</p>	<p align="center">Oral Presentation June 1 (Mon), 11:45-11:57</p>

Major Poster Presentations:

Lenvatinib
(Lenvima[®])